BioMedWire Stocks

Researchers to Explore Link Between Psoriasis and Rheumatoid Arthritis

A new study plans to explore the link between psoriasis and the development of rheumatoid arthritis later in life. Psoriasis is a skin condition with no cure that causes a rash with scaly, itchy patches that are most commonly on the elbows, knees, scalp and trunk. Research has found that roughly one-third of patients with this condition are likely to develop arthritis as they grow older.

The objective of the study, which will be carried out by researchers from Hippocrates, will be focused on discovering common factors between individuals who developed psoriatic arthritis later in life.

While more than 600,000 individuals in the United Kingdom suffer from psoriatic arthritis, researchers are not sure what triggers the condition. Patients living with psoriatic arthritis often present with affected joints becoming stiff, swollen and painful. Early warning signs of psoriatic arthritis include painful swelling in the fingers and toes, fatigue, eye inflammation and redness, stomach issues, changes in one’s nails, scaly patches on knees and elbows, pain in the lower back, tenderness in areas where ligaments or tendons attach to bones, joint stiffness and pain, and difficulty moving.

This condition is usually diagnosed with a physical exam conducted by one’s physician, with treatment being based on how the disease affects a patient’s life.

For their study, the researchers have recruited 2,000 individuals who have already been diagnosed with psoriasis but are yet to present with symptoms of arthritis. Each participant will be tracked for a number of years and will be required to undergo a genetic exam to identify any indicative patterns in the DNA along with regular blood tests.

Scientists hypothesize that certain genes may play a role in psoriasis development, as the illness often runs in families. Obesity and smoking have also been associated with the condition.

One of the researchers involved, Professor Laura Coates, reveals that the researchers will also investigate if an individual’s likelihood of developing arthritis is heightened if their psoriasis is severe, in comparison to those with mild symptoms. Coates, who is a rheumatologist at the University of Oxford, notes that the team will also look into whether the drugs patients use to treat psoriasis have any impact as well as the impact underlying health conditions such as depression and heart disease have.

She hopes that the team’s findings will help physicians better manage psoriatic arthritis, adding that the data may possibly also help discover treatments to stop the condition before it begins to develop.

As researchers delve into the dynamics of how psoriasis could be linked to the eventual onset of rheumatoid arthritis, there are several OTC and prescription psoriasis treatments from multiple sources such as Jupiter Wellness Inc. (NASDAQ: JUPW) that patients can make use of to improve their symptoms.

NOTE TO INVESTORS: The latest news and updates relating to Jupiter Wellness Inc. (NASDAQ: JUPW) are available in the company’s newsroom at https://ibn.fm/JUPW

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The…

7 hours ago

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S.…

1 day ago

Researchers Plan to Investigate Role of Autoantibodies in Cancer Risk, Immune Response

For a long time, scientists have wondered why many individuals that have several risk factors linked to cancer development never…

1 day ago

Earth Science Tech Inc. (ETST) Capitalizing on Diversified, Synergistic Operations to Deliver Dilution-Free and Cash-Flow Driven Growth

Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that…

1 day ago

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision…

2 days ago

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately…

5 days ago